BioPharmSignal logoBioPharmSignal

Biotech News

Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026

Bluejay Diagnostics (BJDX)Bluejay DiagnosticsCompany update

ACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ: BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made substantial progress in advancing manufacturing readiness and technology transfer initiatives

Related news

BJDXBluejay Diagnostics2026-06-02 10:30 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

BJDXBluejay Diagnostics2026-08-13 10:00 EST

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

INBSIntelligent Bio Solutions2026-04-17 12:30 EST

Intelligent Bio Solutions Advances Upcoming FDA 510(k) Submission, Successfully Completes Penetration Testing with No Major Vulnerabilities Identified

FLGTFulgent Genetics, Inc.2026-03-17 20:31 EST

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

INBSIntelligent Bio Solutions2026-02-25 13:45 EST

Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry

FLGTFulgent Genetics, Inc.2025-12-22 21:10 EST

Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

DGXQuest Diagnostics2026-07-08 12:52 EST

Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI

LUCDLucid Diagnostics2026-07-30 12:30 EST

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

VRAXVirax Biolabs2026-07-09 11:30 EST

Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics

DGXQuest Diagnostics2026-06-24 12:52 EST

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

View all latest news

Bluejay Diagnostics

Critical-Care Diagnostics Bluejay Diagnostics develops rapid blood tests for hospital and critical-care settings using its Symphony diagnostic platform. Symphony Platform Symphony is an automated, near-patient testing system designed to provide quantitative biomarker results without relying on a central laboratory workflow. Symphony IL-6...

Recent company news

BJDXBluejay Diagnostics2026-08-13 10:00 EST

Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization

BJDXBluejay Diagnostics2026-07-21 10:30 EST

Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

BJDXBluejay Diagnostics2026-06-06 00:13 EST

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 16:19 EST

Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

BJDXBluejay Diagnostics2026-06-02 10:30 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

Stock data

Close
1.02 USD
Market cap
4.49M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States